Dechra Pharmaceuticals PLC
LSE:DPH
Dechra Pharmaceuticals PLC
Cost of Revenue
Dechra Pharmaceuticals PLC
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Cost of Revenue
-£331.9m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-14%
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Cost of Revenue
-£8.4B
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-1%
|
|
AstraZeneca PLC
LSE:AZN
|
Cost of Revenue
-$8.5B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-5%
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Cost of Revenue
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Indivior PLC
LSE:INDV
|
Cost of Revenue
-$193m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Cost of Revenue
-$1.5B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-9%
|
See Also
What is Dechra Pharmaceuticals PLC's Cost of Revenue?
Cost of Revenue
-331.9m
GBP
Based on the financial report for Jun 30, 2023, Dechra Pharmaceuticals PLC's Cost of Revenue amounts to -331.9m GBP.
What is Dechra Pharmaceuticals PLC's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-14%
Over the last year, the Cost of Revenue growth was -12%. The average annual Cost of Revenue growth rates for Dechra Pharmaceuticals PLC have been -14% over the past three years , -13% over the past five years , and -14% over the past ten years .